Regulation of LRRK2 mRNA stability by ATIC and its substrate AICAR through ARE-mediated mRNA decay in Parkinson's disease

被引:7
|
作者
Liu, Qinfang [1 ]
Zhu, Dong [1 ]
Li, Naren [2 ]
Chen, Shifan [1 ]
Hu, Liang [2 ]
Yu, Jianzhong [2 ]
Xiong, Yulan [1 ]
机构
[1] Univ Connecticut, Sch Med, Dept Neurosci, Farmington, CT 06032 USA
[2] Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT USA
来源
EMBO JOURNAL | 2023年 / 42卷 / 15期
基金
美国国家科学基金会;
关键词
AICAR; AUF1; LRRK2; mRNA decay; Parkinson's disease; ACTIVATED PROTEIN-KINASE; ALPHA-SYNUCLEIN; GENETIC INTERACTIONS; PURINE METABOLISM; BINDING; YEAST; NEURODEGENERATION; PHOSPHORYLATION; DEGRADATION; EXPRESSION;
D O I
10.15252/embj.2022113410
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in LRRK2 are the most common genetic causes of Parkinson's disease (PD). While the enzymatic activity of LRRK2 has been linked to PD, previous work has also provided support for an important role of elevated LRRK2 protein levels, independent of enzymatic activity, in PD pathogenesis. However, the mechanisms underlying the regulation of LRRK2 protein levels remain unclear. Here, we identify a role for the purine biosynthesis pathway enzyme ATIC in the regulation of LRRK2 levels and toxicity. AICAr, the precursor of ATIC substrate, regulates LRRK2 levels in a cell-type-specific manner in vitro and in mouse tissue. AICAr regulates LRRK2 levels through AUF1-mediated mRNA decay. Upon AICAr treatment, the RNA binding protein AUF1 is recruited to the AU-rich elements (ARE) of LRRK2 mRNA leading to the recruitment of the decapping enzyme complex DCP1/2 and decay of LRRK2 mRNA. AICAr suppresses LRRK2 expression and rescues LRRK2-induced dopaminergic neurodegeneration and neuroinflammation in PD Drosophila and mouse models. Together, this study provides insight into a novel regulatory mechanism of LRRK2 protein levels and function via LRRK2 mRNA decay that is distinct from LRRK2 enzymatic functions.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson’s disease
    Alessandro Tozzi
    Michela Tantucci
    Saverio Marchi
    Petra Mazzocchetti
    Michele Morari
    Paolo Pinton
    Andrea Mancini
    Paolo Calabresi
    Cell Death & Disease, 9
  • [32] Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease
    Tozzi, Alessandro
    Tantucci, Michela
    Marchi, Saverio
    Mazzocchetti, Petra
    Morari, Michele
    Pinton, Paolo
    Mancini, Andrea
    Calabresi, Paolo
    CELL DEATH & DISEASE, 2018, 9
  • [33] LRRK2 regulates ferroptosis through the system Xc-GSH-GPX4 pathway in the neuroinflammatory mechanism of Parkinson's disease
    Zheng, Zijian
    Zhang, Shushan
    Liu, Xinjie
    Wang, Xiangrong
    Xue, Cheng
    Wu, Xiao
    Zhang, Xinran
    Xu, Xinping
    Liu, Zheng
    Yao, Longping
    Lu, Guohui
    JOURNAL OF CELLULAR PHYSIOLOGY, 2024, 239 (05)
  • [34] Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics
    Wu, Chun-Xiang
    Liao, Jingling
    Park, Yangshin
    Reed, Xylena
    Engel, Victoria A.
    Hoang, Neo C.
    Takagi, Yuichiro
    Johnson, Steven M.
    Wang, Mu
    Federici, Mark
    Nichols, R. Jeremy
    Sanishvili, Ruslan
    Cookson, Mark R.
    Hoang, Quyen Q.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (15) : 5907 - 5913
  • [35] Resistance to Parkinson's disease among LRRK2 mutation carriers is associated with higher plasma levels of urate but not its purine precursors
    Schwarzschild, M.
    Bakshi, R.
    Logan, R.
    Zorlu, M.
    Chen, X.
    Ascherio, A.
    Macklin, E.
    MOVEMENT DISORDERS, 2018, 33 : S606 - S606
  • [36] Human disease-causing mutations result in loss of leiomodin 2 through nonsense-mediated mRNA decay
    Pappas, Christopher T.
    Mayfield, Rachel M.
    Dickerson, Ava E.
    Mi-Mi, Lei
    Gregorio, Carol C.
    PLOS GENETICS, 2024, 20 (05):
  • [37] LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: Impairment of the kinase activity by Parkinson's disease-associated mutations
    Ohta, Etsuro
    Kawakami, Fumitaka
    Kubo, Makoto
    Obata, Fumiya
    FEBS LETTERS, 2011, 585 (14) : 2165 - 2170
  • [38] LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations
    Ohta, E.
    Kawakami, F.
    Kubo, M.
    Obata, F.
    JOURNAL OF NEUROCHEMISTRY, 2012, 123 : 104 - 104
  • [39] LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations
    Ohta, E.
    Kawakami, F.
    Kubo, M.
    Obata, F.
    FEBS JOURNAL, 2012, 279 : 374 - 374
  • [40] LRRK2 Mediates α-Synuclein-Induced Neuroinflammation and Ferroptosis through the p62-Keap1-Nrf2 Pathway in Parkinson's Disease
    Liu, Xinjie
    Zheng, Zijian
    Xue, Cheng
    Wang, Xiangrong
    Li, Jianwei
    Liu, Zheng
    Xin, Wenqiang
    Xu, Xinping
    Zhou, Dongwei
    Yao, Longping
    Lu, Guohui
    INFLAMMATION, 2025,